Skip to main content
. 2022 Nov 9;12(11):1832. doi: 10.3390/life12111832

Table 1.

Results of cytoprotection assay of synthesized 4-substituted sulfonamidobenzoic acid derivatives against CVB3 Nancy.

Compound ID CC50, (μM) * EC50, (μM) ** SI
2a >710.20 <8.76 >81.1
2b 39.96 ± 4.12 >443.98 <1
2c 472.21 ± 38.17 >474.57 <1
2d 624.66 ± 57.47 743.64 ± 67.32 <1
2e 437.17 ± 35.12 >437.17 <1
2f 181.42 ± 19.21 >688.93 <1
2g >228.31 12.33 ± 2.07 >18.5
2h >725.58 >725.58 >1
2i 283.21 ± 31.09 <28.58 >10
3 >640.35 >426.90 >1
4 >227.27 13.21 ± 1.49 >17.2
7a 344.58 ± 32.16 <9.88 >34.8
7b 473.67 ± 38.52 <8.67 >54.6
7c >684.21 <8.44 >81.1
7d 681.08 ± 54.82 <8.39 >81.1
7e 531.24 ± 48.36 >634.95 <1

* CC50 is the cytotoxic concentration resulting in the death of 50% of the cells; CC50 was evaluated after 72 h of incubation of Vero cells with the compound only. ** EC50 is the 50% cytoprotective concentration leading to 50% cytoprotection after infection of cells with CVB3 at m.o.i 0.001; c SI is the selectivity index, the ratio of CC50/IC50. Compound 2a was used as a reference (positive control). The data presented were obtained from three independent experiments and the values for CC50 and EC50 are mean ± SD.